Medpace Holdings Inc vs Vanguard Growth Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $600 (market cap $16.90B), while Vanguard Growth Index Fund ETF trades at $88.93. Which is the better fit depends on your goals.
| MEDP | VUG | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $620.59 | $90.29 |
52-Week Low | $393.42 | $70.00 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Vanguard Growth ETF (VUG) trades at $89.01, down 0.19% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights strong institutional buying, with multiple firms increasing stakes by over 500% in Q2 2026 (Defense World, August 2026). The ETF focuses on large-cap growth stocks, benefiting from exposure to tech leaders like Microsoft.
The outlook remains positive given institutional accumulation and growth stock momentum, though high RSI levels suggest near-term consolidation risk. Key risks include market volatility and sector concentration, but long-term growth exposure aligns with bullish analyst sentiment.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →